AsiaNet Daily Summary - Press Releases for Monday March 2, 2009

SYDNEY--2 Mar--AsiaNet/InfoQuest


DIABETES PATIENTS...

SYDNEY: Fenofibrate treatment reduces cardiovascular disease (CVD) risk

(defined by total cardiovascular events: the composite of cardiovascular death,
myocardial infarction, stroke, and coronary and carotid revascularization) in
patients with type 2 diabetes and atherogenic dyslipidemia, that is, the
combination of high triglyceride (2.3 mmol/L-200mg/dL or higher) and low
high-density lipoprotein (HDL) cholesterol (<1.03 mmol/L-40mg/dL in men and
<1.3 mmol/L-50mg/dL in women), according to new data from the Fenofibrate
Intervention and Event Lowering in Diabetes (FIELD) study published in Diabetes
Care.

CBEX TO AUCTION...

BEIJING: CBEX (China Beijing Equity Exchange) announced Friday the

auctioning of the fous (an ancient Chinese percussion instrument derived from
clay potteries and bronze ware) that were used in the grand performance of fou
at the opening ceremony of Beijing Olympics Games.

AUSTRALIAN SHAREPOINT ...

SYDNEY: Australian consulting firm, Spyk Software has announced the world's

first application allowing employees to browse and search all their company
documents from their iPhone.
www.spyk.com

PRASUGREL SHOWED...

TOKYO and INDIANAPOLIS: Results from a pre-specified analysis of the

landmark Phase III TRITON-TIMI 38 study showed that patients with the most
severe form of acute coronary syndromes (ACS) undergoing percutaneous coronary
intervention (PCI) achieved a significant reduction in relative risk of the
combined endpoint of cardiovascular death, non-fatal heart attack or non-fatal
stroke at both 30 days and 15 months when treated with prasugrel compared with
clopidogrel (Plavix(R) Iscover(R)).
www.daiichisankyo.com

BECKMAN COULTER...

ORANGE COUNTY: Beckman Coulter, Inc. (NYSE: BEC), a leading developer,

manufacturer, and marketer of products that simplify, automate, and innovate
complex biomedical tests, and Olympus Corporation, a Tokyo-headquartered
precision technology leader, creating innovative opto-digital solutions in
healthcare, life science and consumer electronics products, announced Friday
that they have entered into a definitive agreement under which Beckman Coulter
will acquire the diagnostic systems portion of Olympus' Life Sciences business
for 77.45 billion yen, or approximately US$800 million.
www.beckmancoulter.com

AUSTRALIAN CONSULTING...

SYDNEY: Australian consulting firm, Spyk Software has announced the worlds

first application allowing employees to browse and search all their company
documents from their iPhone.
www.spyk.com

GE HEALTHCARE...

KUALA LUMPUR: GE Healthcare, a leading provider of information technology,

Friday unveiled a suite of Centricity solutions targeted for hospitals and
outpatient imaging centers.
http://www.gehealthcare.com

GE HEALTHCARE...

KUALA LUMPUR: GE Healthcare announced Friday in Asia the release of

Centricity PACS Web Diagnostic (WebDX), a new Web-based diagnostic viewer, best
of breed application that is tightly integrated to Centricity RIS/ PACS, which
bring comprehensive detailed patient history to a single patient folder.
http://www.gehealthcare.com

MALAYSIA AIRLINES...

KUALA LUMPUR: It's low fares galore again as Malaysia Airlines offers all

inclusive one way fares from RM69 for domestic travel, RM170 regional and RM790
for international destinations.
www.malaysiaairlines.com

MALAYSIA AIRLINES...

KUALA LUMPUR" It's low fares galore again as Malaysia Airlines offers all

inclusive one way fares from RM69 for domestic travel, RM170 regional and RM790
for international destinations.
www.malaysiaairlines.com

GMR-HIAL AND MAS...

KUALA LUMPUR: GMR Hyderabad International Airport Ltd. (GHIAL), and MAS

Aerospace Engineering (MAE), a wholly-owned subsidiary of Malaysia Airlines
sealed an agreement today to set up a 50:50 joint venture Airframe Maintenance,
Repair and Overhaul (MRO) company in Hyderabad.

FANNIE MAE...

WASHINGTON, D.C.: Fannie Mae will redeem the principal amount of MTN

securities issues amounting to a total of US$1.278 billion on March 9, March
10, March 11 respectively at a redemption price equal to 100 per cent of the
principal amount redeemed plus accrued interest.
http://www.fanniemae.com

OAG METRICS...

CHICAGO: OAG, the industry's most accurate single source for airline

schedules information, commercial fleets, analytical services and asset
valuation support, has integrated its own metrics to the data just recently
made public by the DOT's Bureau of Transportation Statistics.
www.oagaviation.com

FANNIE MAE SUMMARY...

WASHINGTON: Fannie Maes (NYSE: FNM) January 2009 Monthly Summary is now

available at www.fanniemae.com/ir/monthly.
http://www.fanniemae.com

GLOBAL HUMANITARIAN...

NEW YORK: The Global Humanitarian Forum will be broadcasting live a panel

discussion on Climate Justice hosted by the Global Humanitarian Forum in
collaboration with the University of Pretoria.
www.ghf-geneva.org

HARNESSING THE 'C'...

LONDON and SHANGHAI: China is looking for effective and powerful design

innovation to help cope with the huge challenge of becoming the biggest vehicle
maker in the world within the next few years.
http://www.interiormotivesmagazine.com
http://www.cardesignnews.com
http://www.ultimamedia.com

BOOSTING BUSINESS CONFIDENCE...

LONDON: Britain's executives are being urged to honour the people who make

the most crucial contribution to their businesses: their staff.
www.nationalbusinessawards.co.uk
www.unitedbusinessmedia.com

FORCE 10...

TOKYO: First Japan-Produced Cosmetics and Skincare Products to Earn This

Distinction Force 10 Inc. is pleased to announce that "kawaii TOKYO," its
unique cosmetics and skincare brand now available in Singapore, has become the
first-ever line of Japan-produced skincare products to earn certification under
the "halal" standards of Islamic law.
http://kawaii-tokyo.jp/

AsiaNet is a consortium of leading news agencies distributing unedited,

translated news releases for worldwide clients. Visit www.asianetnews.net for
full-text versions.

ข่าวFenofibrate+o:asnวันนี้

มูลนิธิเชิงวิชาการระดับนานาชาติเผยโครงการวิจัย ACCORD ช่วยสร้างความหวังใหม่ให้กับผู้ป่วยโรคเบาหวานประเภท 2 ที่มีภาวะไขมันในเลือดผิดปกติ

ผู้ป่วยโรคเบาหวานประเภทที่ 2 ที่มีภาวะไขมันในเลือดผิดปกติ (Atherogenic Dyslipidemia) เนื่องจากระดับไตรกลีเซอไรด์ (TG) ในเลือดสูง (204 mg/dL หรือ 2.3 mmol/L หรือสูงกว่า) และมีไฮเดนซิตี้ไลโปโปรตีนคอเลสเตอรอล (HDL-C) ในระดับต่ำ (34 mg/dL หรือ 0.88 mmol/L หรือต่ำกว่า) สามารถลดความเสี่ยงการเกิดโรคหัวใจและหลอดเลือดหัวใจ (Cardiovascular) ได้อีก 31% ด้วยการเพิ่มยา Fenofibrate นอกเหนือจากการใช้ยา Simvastatin ทั้งนี้พบว่าการรักษาผู้ป่วยดังกล่าวจำนวน 20 รายเป็นระยะเวลานาน 5 ปีจะลดการเกิดโรคหัวใจและหลอด

สรุปข่าวเอเชียเน็ทประจำวันจันทร์ที่ 2 มีนาคม 2552

ผู้ป่วยโรคเบาหวาน ซิดนีย์: ข้อมูลฉบับใหม่จากรายงานการศึกษาเรื่อง Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) ที่ตีพิมพ์ลงใน Diabetes Care ระบุว่า การรักษาด้วยยา Fenofibrate ช่วยลดความเสี่ยงในการเกิดโรคหลอดเลือดสมองตีบ(CVD) ...

AsiaNet Daily Summary - Press Releases for Monday March 2, 2009

DIABETES PATIENTS... SYDNEY: Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid...

Diabetes Patients With High Triglycerides and Low HDL Cholesterol get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study

Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial...

สรุปข่าวเอเชียเน็ทประจำวันพุธที่ 10 กันยายน 2551

ยา FENOFIBRATE รักษาโรคเบาหวาน โรม: ข้อมูลจากการศึกษา FIELD บ่งชี้ถึงประโยชน์ของยา Fenofibrate ในการรักษาภาวะตาเสื่อมที่เป็นอาการแทรกซ้อนจากโรคเบาหวาน โดยรายงานครั้งสำคัญนี้จัดทำขึ้นเป็นครั้งแรกเพื่อศึกษาถึงการรักษาระดับลิปิดซึ่งระบุว่า...

AsiaNet Daily Summary - Press Releases for Wednesday, Sept 10, 2008

FENOFIBRATE DIABETES... ROME Exciting New Data From the FIELD Study Show Additional Microvascular-Associated Benefits of Fenofibrate. The First Time in a Large-Scale Prospective Study That any Lipid-Modifying Therapy Has Been Shown...

Fenofibrate Reduces the Risk of Amputations in Patients With Type 2 Diabetes

- Exciting New Data From the FIELD Study Show Additional Microvascular-Associated Benefits of Fenofibrate - The First Time in a Large-Scale Prospective Study That any Lipid-Modifying Therapy Has Been Shown to Significantly...

Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye

In the Lancet, on Tuesday, November, 6th new results of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 2007 clinical trial have been published and presented on the same date at a press conference held during...

สรุปข่าวเอเชียเน็ทประจำวันอังคารที่ 6 พฤศจิกายน 2550

เจแอลที ลี่ซิ่น สิงคโปร์: บริษัทประกัน เจแอลที ลี่ซิ่น (JLT Lixin Insurance Brokers) ขยายการดำเนินงานในจีนด้วยการเปิดสำนักงานสาขาที่นครเซี่ยงไฮ้ ซึ่งสาขาเซี่ยงไฮ้จะช่วยให้ เจแอลที ลี่ซิ่น สามารถใช้ประโยชน์จากผู้เชี่ยวชาญพิเศษนานาชาติ...

AsiaNet Daily Summary, Press Releases for Tuesday, November 6, 2007

JLT LIXIN... SINGAPORE: JLT Lixin Insurance Brokers has expanded its presence in China with a new branch office in Shanghai. The Shanghai branch will allow JLT Lixin to leverage its international specialist expertise, coupled with...